Fasciolosis: pathogenesis, host-parasite interactions, and implication in vaccine development
2023
Luis Miguel Flores-Velázquez | María Teresa Ruiz-Campillo | Guillem Herrera-Torres | Álvaro Martínez-Moreno | Francisco Javier Martínez-Moreno | Rafael Zafra | Leandro Buffoni | Pablo José Rufino-Moya | Verónica Molina-Hernández | José Pérez
Fasciola hepatica is distributed worldwide, causing substantial economic losses in the animal husbandry industry. Human fasciolosis is an emerging zoonosis in Andean America, Asia, and Africa. The control of the disease, both in humans and animals, is based on using anthelmintic drugs, which has resulted in increased resistance to the most effective anthelmintics, such as triclabendazole, in many countries. This, together with the concerns about drug residues in food and the environment, has increased the interest in preventive measures such as a vaccine to help control the disease in endemic areas. Despite important efforts over the past two decades and the work carried out with numerous vaccine candidates, none of them has demonstrated consistent and reproducible protection in target species. This is at least in part due to the high immunomodulation capacity of the parasite, making ineffective the host response in susceptible species such as ruminants. It is widely accepted that a deeper knowledge of the host-parasite interactions is needed for a more rational design of vaccine candidates. In recent years, the use of emerging technologies has notably increased the amount of data about these interactions. In the present study, current knowledge of host-parasite interactions and their implication in Fasciola hepatica vaccine development is reviewed.
显示更多 [+] 显示较少 [-]